Top Markets
#1 Nesa Nesa +797.13%
#2 Cortex Cortex +68.71%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.61%
#4 Pons Pons +24.04%
#5 QuantixAI QuantixAI +23.21%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +17.69%
#8 Renzo Restaked LST Renzo Restaked LST +10.28%
#9 SkyAI SkyAI +9.80%
#10 Fartcoin Fartcoin +9.32%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Rank in Stocks #19673
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Share Price
$3.49
Last synced: 2022-08-12
Market Cap
$154.10M
Change (1 day)
12.28%
Change (1 year)
0.00%
Country
DE
Trade InflaRx N.V. (IF0)

Category

Healthcare
Stock price history for InflaRx N.V. (IF0)
Highest end of day price: $2.95 on 2022-08-01

Lowest end of day price: $3.75 on 2019-12-01
Stock price history of InflaRx N.V. from 2019 to 2026
Annual Stock Price Performance
Year Performance
2022 -31.72%
2021 -9.75%
2020 27.64%
2019 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.60 -12.29%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 7.33%
CH